Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

Advances in first-line treatment for patients with HER-2+ metastatic breast cancer.

De Mattos-Arruda L, Cortes J.

Oncologist. 2012;17(5):631-44. doi: 10.1634/theoncologist.2011-0187. Epub 2012 Apr 20. Review.

PMID:
22523199
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

HER-2-positive metastatic breast cancer: trastuzumab and beyond.

Metro G, Mottolese M, Fabi A.

Expert Opin Pharmacother. 2008 Oct;9(15):2583-601. doi: 10.1517/14656566.9.15.2583 . Review.

PMID:
18803447
[PubMed - indexed for MEDLINE]
3.

Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.

Michalaki V, Fotiou S, Gennatas S, Gennatas C.

Anticancer Res. 2010 Jul;30(7):3051-4.

PMID:
20683054
[PubMed - indexed for MEDLINE]
4.

Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.

Schaller G, Fuchs I, Gonsch T, Weber J, Kleine-Tebbe A, Klare P, Hindenburg HJ, Lakner V, Hinke A, Bangemann N.

J Clin Oncol. 2007 Aug 1;25(22):3246-50. Epub 2007 Jun 18.

PMID:
17577021
[PubMed - indexed for MEDLINE]
Free Article
5.

Docetaxel/trastuzumab combination therapy for the treatment of breast cancer.

Nabholtz JM, Gligorov J.

Expert Opin Pharmacother. 2005 Aug;6(9):1555-64. Review.

PMID:
16086643
[PubMed - indexed for MEDLINE]
6.

Trastuzumab-based combination therapy for breast cancer.

Montemurro F, Valabrega G, Aglietta M.

Expert Opin Pharmacother. 2004 Jan;5(1):81-96. Review.

PMID:
14680438
[PubMed - indexed for MEDLINE]
7.

[Retrospective analysis of trastuzumab treatment in 141 patients with Her-2 positive breast cancer].

Wang Y, Li JJ, DI GH, Lu JS, Wu J, Liu GY, Hu XC, Wang ZH, Yang WT, Shao ZM.

Zhonghua Zhong Liu Za Zhi. 2010 Nov;32(11):864-7. Chinese.

PMID:
21223695
[PubMed - indexed for MEDLINE]
8.

Trastuzumab/chemotherapy combinations in metastatic breast cancer.

Ligibel JA, Winer EP.

Semin Oncol. 2002 Jun;29(3 Suppl 11):38-43. Review.

PMID:
12138396
[PubMed - indexed for MEDLINE]
9.

Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.

Emens LA.

Am J Ther. 2005 May-Jun;12(3):243-53. Review.

PMID:
15891269
[PubMed - indexed for MEDLINE]
10.

HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy.

Jackisch C.

Oncologist. 2006;11 Suppl 1:34-41. Review.

PMID:
16971738
[PubMed - indexed for MEDLINE]
Free Article
11.

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.

Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN.

Oncologist. 2009 Apr;14(4):320-68. doi: 10.1634/theoncologist.2008-0230. Epub 2009 Apr 3. Review.

PMID:
19346299
[PubMed - indexed for MEDLINE]
Free Article
12.

Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.

Nielsen DL, Kümler I, Palshof JA, Andersson M.

Breast. 2013 Feb;22(1):1-12. doi: 10.1016/j.breast.2012.09.008. Epub 2012 Oct 16. Review.

PMID:
23084121
[PubMed - indexed for MEDLINE]
13.

Sensitization of chemotherapy by anti-HER.

Kataoka A, Ishida M, Murakami S, Ohno S.

Breast Cancer. 2004;11(2):105-15. Review.

PMID:
15550854
[PubMed - indexed for MEDLINE]
14.

Trastuzumab treatment beyond progression in advanced breast cancer: patterns of care in six Swiss breast cancer centers.

Huober J, Baumann M, Rochlitz C, Aebi S, Güth U, von Moos R, Müller A, von Rohr L, Widmer I, Thürlimann B.

Oncology. 2011;81(3-4):160-6. doi: 10.1159/000333396. Epub 2011 Oct 28.

PMID:
22041972
[PubMed - indexed for MEDLINE]
15.

Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer.

Martín M, Makhson A, Gligorov J, Lichinitser M, Lluch A, Semiglazov V, Scotto N, Mitchell L, Tjulandin S.

Oncologist. 2012;17(4):469-75. doi: 10.1634/theoncologist.2011-0344. Epub 2012 Mar 30.

PMID:
22467666
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

HER2 overexpressing metastatic breast cancer.

Spigel DR, Burstein HJ.

Curr Treat Options Oncol. 2002 Apr;3(2):163-74. Review.

PMID:
12057079
[PubMed - indexed for MEDLINE]
17.

Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.

Singer CF, Köstler WJ, Hudelist G.

Biochim Biophys Acta. 2008 Dec;1786(2):105-13. doi: 10.1016/j.bbcan.2008.02.003. Epub 2008 Mar 4. Review.

PMID:
18375208
[PubMed - indexed for MEDLINE]
18.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group.

N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7.

PMID:
22149875
[PubMed - indexed for MEDLINE]
Free Article
19.

Pertuzumab in HER2-positive breast cancer.

Sendur MA, Aksoy S, Altundag K.

Curr Med Res Opin. 2012 Oct;28(10):1709-16. doi: 10.1185/03007995.2012.728132. Epub 2012 Oct 11. Review.

PMID:
22953713
[PubMed - indexed for MEDLINE]
20.

Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.

Fleeman N, Bagust A, Boland A, Dickson R, Dundar Y, Moonan M, Oyee J, Blundell M, Davis H, Armstrong A, Thorp N.

Health Technol Assess. 2011;15(42):1-93, iii-iv. doi: 10.3310/hta15420. Review.

PMID:
22152751
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk